Palmitoyl Pentapeptide-4

Palmitoyl Pentapeptide-4 (Matrixyl / Purity ≥98.0%-99.0% HPLC / Powder & Liquid 1000ppm) | Gold Standard Matrikine for Dermal Extracellular Matrix Remodeling, Collagen Synthesis & Deep Wrinkle Erasure

1. Product Overview & Value Proposition

Palmitoyl Pentapeptide-4 (Pal-Lys-Thr-Thr-Lys-Ser-OH, Pal-KTTKS, 棕榈酰五肽-4 / 五胜肽), commercially celebrated under the trade benchmark Matrixyl, represents the foundational biological milestone in peptide cosmeceuticals, cellular matrix redensification, and non-irritating anti-wrinkle dermatology. Originally discovered in wound-healing research directed by the National Institutes of Health (NIH) and developed for advanced skincare by Sederma, Palmitoyl Pentapeptide-4 was the first synthetic matrikine to prove that topical peptides could match the clinical anti-aging efficacy of prescription all-trans-retinoic acid without inducing cutaneous erythema, desquamation, or photo-sensitization. While native KTTKS is a hydrophilic pentapeptide fragment liberated during the physiological enzymatic breakdown of procollagen type I, its poor lipid permeability limited topical transdermal flux. By chemically coupling a lipophilic 16-carbon palmitic acid tail (Pal-) to the N-terminal lysine, modern Palmitoyl Pentapeptide-4 powder achieves a multi-fold increase in skin penetration, diffusing across intercellular lamellar lipids to reach basal fibroblasts in the papillary dermis.

In cutaneous regenerative biophysics, Palmitoyl Pentapeptide-4 functions as an endogenous matrikine feedback messenger. When extracellular collagen undergoes natural mechanical degradation or UV photo-damage, collagen breakdown fragments bind to specific cell-surface receptors on dermal fibroblasts, signaling the need for matrix renewal. Palmitoyl Pentapeptide-4 acts as a biological mimic of this natural messenger fragment. Upon reaching target fibroblasts, it triggers downstream signaling cascades that stimulate the de novo gene transcription and synthesis of type I collagen (upregulated by over 100% to 200%), type III collagen, and type IV anchoring collagen, alongside fibronectin and glycosaminoglycans (GAGs, primarily hyaluronic acid). This coordinated remodeling thickens the depleted dermal-epidermal junction (DEJ), restores dermal ground substance, and pushes out deep structural wrinkles from within. In randomized double-blind human clinical trials, topical formulations containing Palmitoyl Pentapeptide-4 significantly reduced wrinkle depth, wrinkle volume, and skin roughness by over 30% to 45% within 56 days. Our bulk Palmitoyl Pentapeptide-4 active delivers verified performance across primary commercial sectors:

• Clinical Anti-Aging & Matrix Densifying Creams: The gold-standard core active for firming facial moisturizers, deep-line corrective serums, and structural wrinkle-filling emulsions delivering measured clinical rejuvenation.
• Retinol-Alternative & Sensitive-Skin Anti-Wrinkle Regimens: Provides collagen-stimulating results comparable to retinol and retinaldehyde, serving as the premier firming solution for reactive, barrier-compromised, or menopausal skin unable to tolerate retinoid dermatitis.
• Targeted Peri-Orbital & Crow’s Feet Restorative Balms: Thickens fragile periorbital tissue, reconstructs degraded basement membranes, and smooths fine expression crinkles and static eye lines without ocular stinging.
• Neck, Decollete & “Tech-Neck” Crease Emulsions: Synergizes with neuromuscular relaxation peptides (Acetyl Hexapeptide-8) and bio-identical ceramides to fortify thin neck skin against gravitational sagging and horizontal creasing.

As an established bulk Palmitoyl Pentapeptide-4 manufacturer and direct peptide supplier, our processing facilities operate high-throughput automated solid-phase peptide synthesizers, continuous preparative reversed-phase HPLC purification columns, and industrial freeze-drying lyophilization suites. To empower agile skincare brands, formulation laboratories, and contract manufacturing organizations (CMOs), we pair uncompromising analytical quality with flexible commercial terms: accessible low MOQ procurement for benchtop pilot trials, multi-ingredient shipment consolidation across our cosmetic bioactives (Acetyl Hexapeptide-8 Argireline, Copper Tripeptide-1 GHK-Cu, Madecassoside, Ceramide NP, Bakuchiol, Ectoine, L-Ergothioneine, PDRN, Glabridin), and dedicated on-the-ground China-wide raw material sourcing assistance tailored to your exact manufacturing roadmap.

2. Product Specifications (Analytical Quality)

3. Functional Applications (Mechanism of Action)

Deploying pharmaceutical-grade Palmitoyl Pentapeptide-4 across clinical anti-wrinkle creams, pro-collagen eye serums, and dermatological restorative formulations delivers scientifically verified cellular actions:

• Receptor-Mediated Procollagen Type I & III Transcription: Palmitoyl Pentapeptide-4 acts as an intelligent signaling matrikine. Fibroblasts recognize the Lys-Thr-Thr-Lys-Ser amino acid sequence as a native degradation fragment of procollagen type I C-terminal propeptide. Binding to membrane-bound fibroblast receptors activates intracellular kinase cascades, stimulating the transcription of COL1A1, COL1A2, and COL3A1 genes. This drives a documented 100% to 200% surge in procollagen synthesis, replenishing structural dermal collagen density lost to chronological aging.
• Basement Membrane & DEJ Anchoring (Collagen Type IV & Fibronectin): The dermal-epidermal junction (DEJ) flattens with age, leading to skin fragility, mechanical shearing, and sagging. Palmitoyl Pentapeptide-4 upregulates the synthesis of collagen type IV (the primary planar structural mesh of the lamina densa) and fibronectin (the principal cell-adhesion glycoprotein). This reinforces the undulating interdigitations of the DEJ, restoring mechanical anchor strength between the epidermis and dermis.
• Dermal Ground Substance Synthesis (Hyaluronic Acid & GAGs): Beyond structural protein fibers, fibroblasts stimulated by Pal-KTTKS dramatically increase the expression of hyaluronan synthases. This accelerates the production of endogenous glycosaminoglycans (GAGs) and hyaluronic acid within the extracellular matrix, elevating dermal water-binding capacity, plumping sunken tissue, and cushioning deep static creases.
• Retinol-Comparable Efficacy with High Cutaneous Tolerance: In large-scale double-blind human comparative clinical trials, topical Palmitoyl Pentapeptide-4 demonstrated wrinkle-depth and skin-roughness reduction comparable to standard retinol regimens. Crucially, while retinol triggered common retinoid side effects (erythema, localized burning, barrier thinning, and peeling), Pal-KTTKS produced zero barrier disruption or inflammatory desquamation, making it suitable for delicate, sensitive, and dry mature skin types.
• Lipophilic Transdermal Flux & Follicular Delivery: The 16-carbon saturated palmitoyl chain gives the peptide an optimal amphiphilic balance. The fatty acyl tail anchors into stratum corneum intercellular lipid bilayers, enabling smooth partition and passive diffusion down hair follicular conduits and intercellular channels into the viable dermis where target fibroblasts reside.
• Reversible, Non-Toxic Long-Term Matrix Protection: Unlike invasive interventions or harsh chemical peels that create acute trauma to stimulate secondary healing, Palmitoyl Pentapeptide-4 operates as a gentle physiological regulator. It does not induce cellular apoptosis or excessive scarring fibrosis, supporting ongoing collagen turnover across continuous long-term anti-aging regimens.

4. Formulation Combinations & Trending Market Applications

Capitalize on the expanding clinical anti-aging, sensitive-skin anti-wrinkle, and aesthetic medical markets by formulating with our versatile Palmitoyl Pentapeptide-4 portfolio:

• The Master Clinical “Ultimate Wrinkle & Matrix Remodeling” Serum: Our Palmitoyl Pentapeptide-4 (≥99.0% Powder, 0.01%–0.02% or 1,000 ppm Liquid, 3.0%–5.0%) + Acetyl Hexapeptide-8 (Argireline ≥99.0%, 0.05% or 1,000 ppm Liquid, 5.0%) + Copper Tripeptide-1 (GHK-Cu ≥99.0%, 0.1%) + Multi-Molecular Weight Sodium Hyaluronate (1.0%) + Propanediol (5.0%). The globally recognized benchmark dual-action matrix: Pal-KTTKS rebuilds structural collagen I/III and restores DEJ thickness, Argireline blocks dynamic expression creasing, GHK-Cu balances tissue remodeling, and Hyaluronic Acid provides immediate multi-depth plumping.
• The “Retinol-Alternative & Barrier-Nourishing” Night Balm: Our Palmitoyl Pentapeptide-4 (≥98.0%, 0.01%) + Bakuchiol (≥99.0%, 1.0%) + Ceramide NP (≥98%, 0.2%) + Madecassoside 95% (0.2%) + Plant-Derived Squalane (6.0%). A luxurious restorative cream delivering retinol-rivaling collagen synthesis without dry flaking or irritation, designed to rebuild the intercellular lipid barrier and plump static facial wrinkles.
• The Targeted “Peri-Orbital Crow’s Feet & Eye-Lift” Elixir: Our Palmitoyl Pentapeptide-4 (1,000 ppm Liquid, 4.0% delivering 40 ppm active) + Acetyl Tetrapeptide-5 (Eyeseryl, 3.0%) + Caffeine Anhydrous (USP, 1.0%) + Niacinamide (≥99.5%, 2.0%) + Ectoine (≥99.0%, 1.0%). An advanced eye-contour treatment designed to densify thin periorbital tissue, reduce static crow’s feet lines, drain microvascular puffiness, and brighten under-eye shadows.
• The “Post-Laser & Aesthetic Recovery” Firming Emulsion: Our Palmitoyl Pentapeptide-4 (1,000 ppm Liquid, 3.0%) + PDRN (Sodium DNA ≥98%, 0.2%) + Tranexamic Acid (USP, 2.0%) + D-Panthenol (Vitamin B5, 2.0%) + Ceramide NP (Water-Soluble Nano-Liposomal 5%, 2.0%). A high-tolerance, fragrance-free recovery elixir engineered for post-procedure care to clear procedural erythema, prevent rebound pigmentation, and accelerate dermal collagen re-anchoring.

5. Why Choose Us As Your Long-Term Peptide Partner?

• Flexible Low MOQ Policy: Mitigate product launch risk. As an agile low MOQ Palmitoyl Pentapeptide-4 bulk supplier, our orders start as low as 10 g for ultra-pure clinical lyophilized powder (≥99.0%), 100 g for standard cosmetic powder (≥98.0%), and 1 kg for pre-solubilized liquid solutions (100–1,000 ppm), scaling smoothly up to recurring multi-kilogram commercial production contracts.
• 100% SPPS Sequence Precision & High Palmitoylation Yield: Synthesized using automated solid-phase Fmoc-peptide chemistry. Our proprietary coupling protocol ensures over 98% complete palmitoylation of the N-terminal lysine, preventing unacylated KTTKS fragments that fail to cross stratum corneum barriers.
• Multi-Product Portfolio Consolidation: Streamline your procurement by sourcing your complete peptide and barrier active suite (Palmitoyl Pentapeptide-4, Acetyl Hexapeptide-8 Argireline, Copper Tripeptide-1 GHK-Cu, Madecassoside, Ceramide NP, Bakuchiol, Ectoine, L-Ergothioneine, PDRN, Tranexamic Acid, Glabridin), longevity vitamins (L-5-MTHF-Ca, β-NMN), and botanical extracts under a single, cost-effective freight shipment to reduce customs overhead and landed freight costs.
• Value-Added China Sourcing Service: In addition to our dedicated solid-phase peptide synthesis suites, preparative HPLC purification columns, and industrial lyophilization plants, our on-the-ground technical team audits upstream amino acid raw materials, validates RP-HPLC purity testing paperwork, and procures specialized functional ingredients across China tailored to your exact manufacturing roadmap.

6. Quality & Supply Chain Assurance

• Solid-Phase Peptide Synthesis (SPPS) Precision: Synthesized step-by-step from the C-terminal serine on specialized Wang resin supports using protected L-amino acids. The final peptide chain is coupled to high-purity palmitic acid, cleaved from resin, and purified via preparative reversed-phase HPLC, followed by sterile micro-filtration and clean freeze-drying.
• Zero Synthetic Racemization: Tested via chiral amino acid analysis (AAA) and electrospray ionization mass spectrometry (ESI-MS). We certify 100% all-L stereoisomer configuration, verifying the complete absence of inactive D-amino acid racemization artifacts, truncated peptide chains, or free fatty-acid contaminants.
• Formulation Compatibility & Spontaneous Dissolution: Pure lyophilized powder dissolves readily in water/glycol co-solvent systems, producing an optically clear solution without precipitate. For direct cold-process manufacturing, our standardized 1,000 ppm aqueous/glycolic solution can be metered directly into the water phase or cool-down phase below 40°C–45°C.
• Broad pH Stability & Emulsion Integrity: Palmitoyl Pentapeptide-4 is stable across a broad cosmetic pH window of 4.5 to 7.0. It is fully compatible with non-ionic, anionic, and cationic emulsifiers, hyaluronic acid gels, and common cosmetic thickeners (carbomer, xanthan gum) without thinning or phase separation.
• Comprehensive ICP-MS & Heavy Metal Screening: Batch-tested via high-resolution ICP-MS to ensure heavy metals (Lead, Arsenic, Cadmium, Mercury) strictly comply with California Prop 65, European Cosmetic Regulation (EC) No 1223/2009, and China Safety and Technical Standards for Cosmetics. Sealed in sterile, light-proof pharmaceutical glass vials (10 g, 50 g, 100 g) and multi-layer fluorinated aluminum canisters (1 kg).

7. FAQ

Q1: What is the biological mechanism difference between Palmitoyl Pentapeptide-4 (Matrixyl) and Acetyl Hexapeptide-8 (Argireline)?
A1: Both are celebrated anti-aging peptides, but they address entirely different biological facets of wrinkle formation:

• Palmitoyl Pentapeptide-4 (Matrixyl): Operates as a structural collagen-stimulating matrikine in the dermis. It signals fibroblasts to synthesize new type I, III, and IV collagen, fibronectin, and hyaluronic acid. It treats resting, static wrinkles, loose skin, and depleted dermal volume by rebuilding the extracellular matrix from beneath.
• Acetyl Hexapeptide-8 (Argireline): Operates as a neuromuscular relaxation peptide. It destabilizes the presynaptic SNARE complex, reducing acetylcholine exocytosis to soften muscle micro-contractions. It primarily treats dynamic expression lines (such as crow’s feet and forehead frown lines). Formulating both peptides together creates the industry-benchmark synergy addressing both dynamic creasing and static collagen loss.

Q2: Why is the palmitoyl group (Pal-) attached to the KTTKS pentapeptide?
A2: Native KTTKS is a small, hydrophilic peptide fragment (Lys-Thr-Thr-Lys-Ser). While biologically active in cell culture, its polar hydrophilic charges prevent it from crossing the lipophilic stratum corneum of human skin. Conjugating a 16-carbon saturated palmitic acid fatty acid tail to the N-terminus creates an amphiphilic molecule. The palmitoyl chain anchors into stratum corneum lipid bilayers, increasing transdermal penetration by several-fold and ensuring that the peptide reaches viable basal fibroblasts in the papillary dermis.

Q3: How does Palmitoyl Pentapeptide-4 compare clinically to Retinol?
A3: In large-scale double-blind human clinical trials conducted over 12 weeks:

• Anti-Wrinkle Efficacy: Palmitoyl Pentapeptide-4 achieved wrinkle-depth and volume reduction comparable to all-trans-retinol (reducing deep wrinkles by over 30% to 45%).
• Skin Barrier & Irritation: While retinol frequently provoked significant peeling, transepidermal water loss (TEWL) spikes, and erythema, Pal-KTTKS caused zero barrier disruption, stinging, or redness. It improves skin hydration and barrier resilience, making it the preferred anti-aging active for consumers unable to tolerate traditional retinoids.

Q4: What is the recommended usage percentage of Palmitoyl Pentapeptide-4 in finished cosmetic formulations?
A4: Formulating percentages vary by delivery format and target clinical claim:

• Using Standardized 1,000 ppm Aqueous/Glycol Solution: Formulate at 3.0% to 5.0% (delivering 30 ppm to 50 ppm active peptide; 3.0% to 5.0% represents the classic clinical benchmark).
• Using Pure Lyophilized Crystalline Powder: Formulate at 0.003% to 0.01% (30 ppm to 100 ppm pure active).
• Targeted Deep Wrinkle Balms & Peri-Orbital Eye Creams: Formulate at 4.0% to 5.0% of 1,000 ppm liquid (or 0.005%–0.01% pure powder).
• Formulating Window: Optimal pH is 4.5 to 7.0; add during the cool-down phase below 40°C–45°C.

Q5: What is the MOQ for bulk Palmitoyl Pentapeptide-4 orders?
A5: We support agile product commercialization with flexible minimum order quantities starting from just 10 g for ultra-pure clinical lyophilized powder (≥99.0%), 100 g for standard cosmetic grade (≥98.0%), and 1 kg for pre-solubilized liquid solutions (100–1,000 ppm), scaling smoothly up to recurring multi-kilogram commercial production contracts.

8. References

1. PubChem: Palmitoyl Pentapeptide-4 Compound Summary (CID 46781745) – National Center for Biotechnology Information.
2. PubMed Central: Topical Palmitoyl Pentapeptide-4 in the Reversal of Cutaneous Extracellular Matrix Degradation: A Double-Blind Placebo-Controlled Clinical Evaluation – National Institutes of Health research database.

Keywords you may search: bulk Palmitoyl Pentapeptide-4 supplier, Matrixyl peptide manufacturer, palmitoyl pentapeptide-4 powder 99 percent HPLC, Pal-KTTKS procollagen matrikine bulk, anti wrinkle peptide cosmetic ingredient, palmitoyl pentapeptide 1000ppm liquid, dermal matrix remodeling peptide raw material, collagen stimulating peptide bulk, low MOQ cosmetic peptide provider, custom China ingredient sourcing service, pure palmitoyl pentapeptide-4 bulk